For the quarter ending 2025-06-30, ATAI had $34,435K increase in cash & cash equivalents over the period. -$32,330K in free cash flow.
| Cash Flow | 2025-06-30 |
|---|---|
| Stock-based compensation expense | 6,041 |
| Net gain (loss) | -54,211 |
| Prepaid expenses and other current assets | -1,281 |
| Accrued liabilities | 3,975 |
| Accounts payable | 813 |
| Loss on extinguishment of debt | -1,317 |
| Gain on other investments | 3,794 |
| Unrealized foreign exchange (gain) loss | 1,949 |
| Depreciation and amortization of long-term assets | 443 |
| Amortization of debt discount | 176 |
| Issuance costs allocated to pre-funded warrants | 706 |
| Other expense, net | -883 |
| Noncash lease expense | 240 |
| Losses from investments in equity method investees, net of tax | 0 |
| Noncash change in the fair value of digital assets, net | 1,216 |
| Noncash change in the fair value of assets and liabilities, net | -13,360 |
| Net cash used in operating activities | -31,935 |
| Proceeds from sale of other investment held at fair value | 3,856 |
| Proceeds from sale and maturities of securities carried at fair value | 11,059 |
| Cash paid for capitalized internal-use software development costs | 0 |
| Cash paid for property and equipment | 395 |
| Cash paid for investments | 10,000 |
| Cash paid for digital assets | 5,000 |
| Cash paid for securities carried at fair value | 0 |
| Cash paid for short term notes receivable - related party | 0 |
| Cash paid for short-term convertible notes receivable and warrant - related party | 0 |
| Cash paid for asset acquisition | 750 |
| Net cash provided by (used in) investing activities | -1,230 |
| Proceeds from issuance of shares upon exercise of stock options | 1,632 |
| Proceeds from equity offerings, net | 78,159 |
| Proceeds from warrant issuance | 11,549 |
| Cash paid for debt extinguishment | 21,811 |
| Cash paid for common stock issuance costs | -2,167 |
| Net cash provided by financing activities | 67,362 |
| Effect of foreign exchange rate changes on cash | 238 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 34,435 |
ATAI Life Sciences N.V. (ATAI)
ATAI Life Sciences N.V. (ATAI)